misleading statements

Law firm sues uniQure for allegedly misrepresenting gene therapy trial status and FDA approval timeline, causing stock to surge 250% then fall 49% after FDA reversal.

Rosen Law Firm sues Sallie Mae for false disclosures on loan delinquencies. Investors have until February 17, 2026 deadline to join the class action lawsuit.

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.

Klarna faces securities lawsuit alleging it concealed loss reserve increases in its September 2025 IPO. Investors have until February 20 to join the class action.

Class action lawsuit filed against Fermi Inc. alleging material misrepresentations in October 2025 IPO regarding Project Matador demand and financial viability disclosures.

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.

uniQure faces securities lawsuit alleging misleading statements about AMT-130's FDA pathway. Stock dropped 49% after FDA reversed stance. Investors have April deadline for lead plaintiff claims.

Law firm sues Oracle for allegedly misleading investors about AI spending's near-term revenue potential. Stock fell 11% after earnings missed expectations.

Vistagen faces securities class action over alleged misleading statements about drug fasedienol. Investors who purchased stock April 2024-December 2025 can join by March 16, 2026 deadline.

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.

Vistagen's failed drug trial caused 81% stock drop. Securities lawsuit filed for investors who bought shares April 2024-December 2025. Lead plaintiff deadline: March 16, 2026.

AGL faces securities fraud allegations over false 2025 guidance. Stock plunged 51.5% after guidance suspension; investors have until March 2026 deadline to join class action.

Law firm investigates Ramaco Resources for alleged securities fraud over inactive Wyoming mine despite reported groundbreaking. Class action deadline: March 31, 2026.

Pomdoctor investors must act by April 13, 2026, to join securities fraud class action alleging false statements and manipulated trading volumes that caused stock decline.

Rosen Law Firm sues Picard Medical for securities fraud involving false statements and market manipulation. Investors must act by April 13, 2026 deadline.

Ultragenyx faces class action lawsuit alleging false statements about its osteogenesis imperfecta drug's efficacy after Phase III trial failed to meet primary endpoint.

Oracle faces securities fraud class action for allegedly misleading investors about AI infrastructure investments requiring substantial capital with minimal near-term revenue generation.

Class action lawsuit filed against Plug Power for allegedly making false statements about hydrogen facility development and DOE loan prospects. Investors who bought securities between January-November 2025 eligible.

Four companies face securities fraud lawsuits alleging false statements to investors. Shareholders have until March 2026 to become lead plaintiffs in the class actions.

Investors in Mereo BioPharma face April deadline in class action lawsuit alleging executives misrepresented clinical trial results for setrusumab drug, causing stock losses.